Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines.
暂无分享,去创建一个
M. Rotondi | M. Serio | C. Crescioli | M. Mannelli | F. Santeusanio | A. Bellastella | A. De Bellis | P. Romagnani | P. Ferruzzi | S. Laureti | E. Lazzeri | A. Falorni | A. Buonamano
[1] M. Rotondi,et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. , 2004, The Journal of clinical endocrinology and metabolism.
[2] G. Arnaldi,et al. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.
[3] Gabriella Nesi,et al. Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.
[4] S. Bornstein,et al. Cytokines and steroidogenesis , 2004, Molecular and Cellular Endocrinology.
[5] A. Weetman,et al. Detection and localization of chemokine gene expression in autoimmune thyroid disease , 2003, Clinical endocrinology.
[6] M. Rotondi,et al. —to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-α-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107–1110 , 2003, Diabetologia.
[7] L. Ivashkiv,et al. Inhibition of IFN-γ Signaling by Glucocorticoids1 , 2003, The Journal of Immunology.
[8] M. Rotondi,et al. Role for interferon-γ inducible chemokines in endocrine autoimmunity: An expanding field , 2003 .
[9] F. Nicoletti,et al. Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease , 2002, Diabetologia.
[10] Luca Chiovato,et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. , 2002, The American journal of pathology.
[11] F. Mantero,et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. , 2002, Endocrine reviews.
[12] E. Husebye,et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. , 2002, The Journal of clinical endocrinology and metabolism.
[13] F. Sánchez‐Madrid,et al. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. , 2001, The Journal of clinical endocrinology and metabolism.
[14] T. Giordano,et al. Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. , 2001, The Journal of clinical endocrinology and metabolism.
[15] Maria I. New,et al. Addison’s Disease 2001 , 2001 .
[16] R. Bergamaschi,et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies , 2001, Journal of Neuroimmunology.
[17] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[18] Y Oikawa,et al. Elevated serum IP-10 levels observed in type 1 diabetes. , 2001, Diabetes care.
[19] T. Okanoue,et al. Increase of chemokine interferon‐inducible protein‐10 (IP‐10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes , 2001, Clinical and experimental immunology.
[20] T. Takeuchi,et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. , 2000, Cytokine.
[21] R. Uibo,et al. Adrenal Autoimmunity: Results and Developments , 2000, Trends in Endocrinology & Metabolism.
[22] E. Arvat,et al. Low dose (1 μg) ACTH test in the evaluation of adrenal dysfunction in pre‐clinical Addison's disease , 2000, Clinical endocrinology.
[23] P. Brunetti,et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies , 2000, Clinical endocrinology.
[24] D. Franchimont,et al. Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 , 2000, The Journal of Immunology.
[25] A. Zlotnik,et al. Chemokines: a new classification system and their role in immunity. , 2000, Immunity.
[26] F. Santeusanio,et al. Is the prevalence of Addison's disease underestimated? , 1999, The Journal of clinical endocrinology and metabolism.
[27] F. Santeusanio,et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. , 1998, The Journal of clinical endocrinology and metabolism.
[28] M. Karin. New Twists in Gene Regulation by Glucocorticoid Receptor: Is DNA Binding Dispensable? , 1998, Cell.
[29] R. Strieter,et al. The role of CXC chemokines in the regulation of angiogenesis in non‐small cell lung cancer , 1997, Journal of leukocyte biology.
[30] S J Gange,et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. , 1997, Clinical immunology and immunopathology.
[31] B. Rousset,et al. Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. , 1995, The Journal of clinical investigation.
[32] W. Scherbaum,et al. Macrophages within the human adrenal gland , 1994, Cell and Tissue Research.
[33] D. Boumpas,et al. Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.
[34] A. Weetman,et al. Adrenocorticotropic hormone receptor-blocking immunoglobulins in serum from patients with Addison's disease: a reexamination. , 1993, The Journal of clinical endocrinology and metabolism.
[35] A. Bellastella,et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. , 1993, The Journal of clinical endocrinology and metabolism.
[36] A. Weetman,et al. T and B cell reactivity to adrenal antigens in autoimmune Addison's disease , 1992, Clinical and experimental immunology.
[37] T. Yokochi,et al. Experimental autoimmune adrenalitis: a murine model for Addison's disease. , 1992, Autoimmunity.